A trial looking at giving R-CHOP chemotherapy with bevacizumab for diffuse large B cell lymphoma (R-CHOP-B)

Coronavirus (COVID-19)

We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.

Read about coronavirus and cancer

Cancer type:

Blood cancers
High grade lymphoma
Non-Hodgkin lymphoma




Phase 2

This trial was looking at giving R-CHOP chemotherapy with bevacizumab to treat diffuse large B cell lymphoma. This trial was supported by Cancer Research UK.

Diffuse large B cell lymphoma (DLBCL) is a type of high grade non Hodgkin lymphoma. Doctors usually treat DLBCL with a combination of drugs - rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone. They call this R-CHOP.

In order to grow and multiply, all cells - including tumour cells - need a good blood supply. To encourage blood vessel growth, cells produce a substance called vascular endothelial growth factor (VEGF). We know from research that high levels of VEGF may affect how well R-CHOP works for some people with DLBCL.

Bevacizumab is a type of biological therapy that targets VEGF. This stops the lymphoma from developing the blood vessels that it needs in order to grow. The researchers gave bevacizumab with R-CHOP to find out if it could help people with DLBCL.

The aims of this trial were to find out

  • The side effects of giving bevacizumab to people with DLBCL
  • The side effects of giving bevacizumab and R-CHOP (R-CHOP-B)
  • How well the combination of bevacizumab and R-CHOP worked for people with DLBCL

Summary of results

This trial was never finished so there are no results available.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Prof David Cunningham

Supported by

Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
Institute of Cancer Research (ICR)
National Institute for Health Research Cancer Research Network (NCRN)
The Royal Marsden NHS Foundation Trust

Other information

This is Cancer Research UK trial number CRUK/08/029.

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 3150

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Wendy took part in a new trial studying the possible side effect of hearing loss

A picture of Wendy

"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think